218 related articles for article (PubMed ID: 11589265)
1. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
Condemi JJ
Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
[TBL] [Abstract][Full Text] [Related]
2. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease.
Vervloet D; Ekström T; Pela R; Duce Gracia F; Kopp C; Silvert BD; Quebe-Fehling E; Della Cioppa G; Di Benedetto G
Respir Med; 1998 Jun; 92(6):836-42. PubMed ID: 9850367
[TBL] [Abstract][Full Text] [Related]
3. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
Brambilla C; Le Gros V; Bourdeix I;
Clin Ther; 2003 Jul; 25(7):2022-36. PubMed ID: 12946548
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
Nightingale JA; Rogers DF; Barnes PJ
Chest; 2002 May; 121(5):1401-6. PubMed ID: 12006420
[TBL] [Abstract][Full Text] [Related]
5. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
6. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
7. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
[TBL] [Abstract][Full Text] [Related]
8. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
9. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
10. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
11. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
13. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
14. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
15. Salmeterol xinafoate in children on high dose inhaled steroids.
Russell G; Williams DA; Weller P; Price JF
Ann Allergy Asthma Immunol; 1995 Nov; 75(5):423-8. PubMed ID: 7583864
[TBL] [Abstract][Full Text] [Related]
16. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma.
Molimard M; Bourcereau J; Le Gros V; Bourdeix I; Leynadier F; Duroux P;
Respir Med; 2001 Jan; 95(1):64-70. PubMed ID: 11207020
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
Rabe KF; Timmer W; Sagkriotis A; Viel K
Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
[TBL] [Abstract][Full Text] [Related]
18. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.
Bodzenta-Lukaszyk A; Dymek A; McAulay K; Mansikka H
BMC Pulm Med; 2011 May; 11():28. PubMed ID: 21605396
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
20. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
Hanrahan JP; Grogan DR; Baumgartner RA; Wilson A; Cheng H; Zimetbaum PJ; Morganroth J
Medicine (Baltimore); 2008 Nov; 87(6):319-328. PubMed ID: 19011503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
